Viewing Study NCT06589804


Ignite Creation Date: 2025-12-24 @ 7:58 PM
Ignite Modification Date: 2026-01-05 @ 5:54 PM
Study NCT ID: NCT06589804
Status: RECRUITING
Last Update Posted: 2025-12-24
First Post: 2024-09-06
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Sponsor: National Cancer Institute (NCI)
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module